According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Nanox’s 510(k) application for the Nanox.ARC (an imaging system that uses a purportedly novel X-ray source) was deficient;
- accordingly, it was unlikely that the U.S. Food and Drug Administration (the “FDA”) would approve the 510(k) application for the Nanox.ARC in its current form;
- as a result, Nanox had overstated Nanox.ARC’s regulatory and commercial prospects; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.